What are the fundraising trends in the femtech market?
In our femtech market deck, you will find everything you need to understand the market
SUMMARY
We analyzed every publicly disclosed equity round raised by pure-play femtech companies between January 2024 and May 2026, using a $300K minimum disclosed deal size, equity-only financing filter, and a pure-play rule focused on women’s reproductive and female-specific health. The resulting sample covers 108 deals across 107 unique companies, including 39 deals in 2024, 49 deals in 2025, and 20 deals from January through May 2026.
The femtech market is active, but it is not in a broad funding boom. Full-year capital was roughly flat from $809.77M in 2024 to $820.525M in 2025, while year-to-date 2026 capital reached $225.325M, slightly below the comparable early-2025 period.
Deal count is healthier than dollar growth. The femtech market moved from 39 deals in 2024 to 49 deals in 2025, and year-to-date 2026 already has 20 qualifying deals, but the average and median round sizes show that more companies are raising smaller checks.
Capital remains highly concentrated. In 2026 so far, Midi Health’s $100M Series D+ accounts for 44.4% of all capital, and the top three deals account for 62.6%, which means the headline total depends heavily on a small number of proven companies.
The typical femtech round is much smaller than the headline average suggests. The 2026 year-to-date median round is $4.7M, while the average is $11.266M, so outlier rounds are pulling the average far above what most funded companies actually receive.
Hormonal Health Platforms lead year-to-date 2026 by capital, with $114.6M, or 50.9% of the total. That strength is real, but it is also concentrated, because Midi Health alone explains most of the category’s current dollar dominance.
Women’s Primary Care leads year-to-date 2026 by deal count, with 6 of 20 deals. The practical signal is that diagnostics, breast cancer screening, ovarian cancer testing, reproductive care coordination, and sex-specific biology are becoming a broader investment surface.
North America remains the capital engine of the femtech market. It captured 81.7% of year-to-date 2026 funding, compared with 14.7% for Europe, while Europe continues to show more company-formation momentum than scale-financing momentum.
First financings are still entering the femtech market, but they are not where most dollars go. In 2026 so far, first financings represent 35% of deals and 15% of capital, which confirms that new startups can raise, but follow-on companies still absorb most of the money.
The strongest interpretation is selective growth. The femtech market is producing more funded companies across fertility, pregnancy, hormonal health, menstrual health, pelvic care, and women’s primary care, but large checks are concentrating around businesses with clinical proof, payer relevance, provider workflows, regulatory credibility, or platform-scale retention.
This chart, featured in our femtech market deck, illustrates how revenue is divided among customer segments in the femtech market
Is more or less capital going into the femtech market?
More capital is not really going into the femtech market in a broad-based way. The cleanest answer is that femtech funding is roughly flat at the headline level, while the quality and concentration of that capital are changing underneath.
The full-year comparison looks stable. Qualifying femtech companies raised about $810M in 2024 and about $821M in 2025, which is only a small increase of roughly 1%. Deal count rose more meaningfully, from 39 deals to 49 deals, so the femtech market broadened by number of financings without materially expanding the total capital pool.
The freshest year-to-date comparison is less encouraging. From January through May 2026, the femtech market raised about $225M across 20 deals, compared with about $229M across 17 deals over the comparable 2025 period. That means deal activity is up, but dollars are slightly down.
The practical takeaway is that the femtech market is active but not accelerating. Investors are still funding the category, but they are spreading capital across more companies and reserving the largest checks for a small number of proven winners.
This is why headline funding totals need to be read carefully. A year can look strong because one or two companies raised very large rounds, even if the underlying market for the typical company is much tighter.
Is femtech funding driven by more deals or larger rounds?
Femtech funding is being driven more by more deals than by larger rounds. The number of funded companies is rising, but the average round size has fallen, and the typical 2026 financing is much smaller than the typical comparable 2025 financing.
From January through May 2026, the femtech market had 20 qualifying deals, compared with 17 over the same period in 2025. But average round size fell from about $13.5M to about $11.3M, while the median round fell from $10M to about $4.7M. That means more companies are raising, but most are raising smaller checks.
The full-year comparison points in the same direction. In 2025, deal count rose by about 26% versus 2024, while total capital rose by only about 1%. Average round size fell from about $20.8M in 2024 to about $16.8M in 2025.
The honest interpretation is that founder formation and investor experimentation are healthy, but broad-based scale-up financing remains selective. The femtech market is not being lifted by generally larger rounds; it is being lifted by more transactions, with occasional large rounds changing the headline total.
For deeper benchmarks on femtech round sizes, medians, and funding concentration, see the full femtech market report.
Is femtech capital moving toward later-stage or earlier-stage companies?
Femtech capital is moving in two directions at once. By deal count, the market remains early-stage-heavy, but by dollars, year-to-date 2026 has shifted back toward later-stage winners.
In 2026 so far, seed rounds represent 50% of all deals, Series A adds another 20%, and Series B or later accounts for only 10% of deal count. That means the company-formation layer is still active and early.
But the capital distribution tells a different story. Series B and later rounds captured 53.7% of year-to-date 2026 capital, mainly because Midi Health raised $100M and Origin raised $21M. Over the comparable 2025 period, Series B and later rounds captured only about 25% of capital, so the freshest dollar signal has moved later-stage.
The full-year comparison adds nuance. In 2024, late-stage rounds captured about 86% of all capital, while in 2025 early and non-Series B+ rounds captured about 56%. So 2025 looked more Series A-centered after 2024’s late-stage-heavy cycle, but 2026 has swung back toward a few scaled companies.
The practical takeaway is that the femtech market is barbell-shaped. A lot of companies are still raising early checks, but most of the money is going to the few companies that have crossed meaningful proof thresholds.
This chart, included in our femtech market deck, compares the main business model options for menopause telehealth platforms
Is the femtech market maturing or still experimental?
The femtech market is maturing at the top but still experimental underneath. The strongest companies can raise large institutional rounds, while the long tail remains seed-heavy and relatively underfunded.
The maturity signal is visible in the companies that keep attracting large checks. In 2024, Maven, Flo Health, Comanche Biopharma, Midi Health, Natural Cycles, and Pomelo Care all raised major rounds. In 2025, large financings went to companies such as ReproNovo, Mercy BioAnalytics, Diana Health, Visby Medical, Midi Health, Conceivable Life Sciences, and Gameto. In 2026 so far, Midi Health and Origin show that scaled femtech companies can still access meaningful capital.
But the experimental layer is just as important. In 2026 so far, seed rounds account for half of all deals but only 12.5% of capital, and the median seed round is about $1.6M. That is not a mature funding base for a market where many companies face clinical validation, reimbursement, hardware development, provider integration, or regulatory workflows.
The better answer is that femtech is not immature because it lacks serious companies. It is immature because many subcategories still lack repeatable funding ladders from seed to Series B. The market has credible leaders, but it has not yet produced scaled winners evenly across every category.
The strongest way to read the femtech market is as a barbell: maturing leaders at the top, experimental company formation at the bottom, and a still-thin middle.
Are new startups still entering the femtech market?
Yes, new startups are still entering the femtech market, but new-company formation should not be confused with broad investor conviction. First financings remain visible, while most capital still goes to follow-on companies.
From January through May 2026, first financings represented 7 of 20 deals, or 35% of deal count. Those first financings captured about $34.6M, or 15% of capital. That is a stronger capital share than the comparable early-2025 period, when first financings represented about 12% of deals and only 3.5% of capital.
The improvement is encouraging, but it needs context. ONTO Health’s $20M Series A lifted the 2026 first-financing capital total meaningfully. Without that one deal, the new-entrant capital base would look much smaller.
The full-year pattern is more restrained. In 2024, first financings were about 39% of deals and captured only about 6% of capital. In 2025, first financings were about 29% of deals and again captured only about 6% of capital.
The real signal is that the femtech market remains open to new entrants, especially in diagnostics, AI-enabled workflows, fertility infrastructure, menopause and hormonal health, and women’s primary care. But new entrants need a sharper proof story than category participation alone.
For more context on femtech startup formation and first-financing patterns, see the femtech market deck.
Are more investors entering the femtech market?
Yes, more investors appear to be entering or at least sampling the femtech market. The more important point is that the investor base is broad but fragmented, with limited repeat behavior.
In 2026 so far, the femtech market shows about 57 unique disclosed investors and about 15 identifiable tier-1 or high-quality strategic investors across only 20 deals. That is a meaningful level of participation for a still-specialized healthcare category.
The investor mix includes healthcare specialists, generalist venture firms, strategic investors, women-focused funds, angel networks, and regional capital. That breadth suggests femtech is no longer viewed only as a niche impact theme.
But no investor appears more than once across the disclosed 2026 year-to-date syndicates after excluding generic existing investors and undisclosed participants. That matters because repeat investors create category learning, follow-on confidence, pricing discipline, and stronger underwriting standards.
The best answer is that more investors are participating in femtech, but not enough investors are behaving like repeat category owners. The market is attracting attention from many directions, but it has not yet built the dense specialist investor ecosystem seen in more mature venture categories.
This chart, included in our femtech market deck, shows annual funding in femtech startups
Are top investors getting more or less active in femtech?
Top investors are still active in the femtech market, but their activity looks more selective and less repeat-driven than in 2024. The strongest investors are concentrating around clinically legible, scaled, or infrastructure-like companies rather than broadly funding the entire category.
In 2024, top-investor activity was especially visible. GV participated in four qualifying deals, including Comanche Biopharma, Oula, Midi Health, and Maven. Other major names included NEA, Atlas Venture, F-Prime, 8VC, Emerson Collective, Felicis, Sofinnova, RA Capital, Insight Partners, Point72, EQT Ventures, Andreessen Horowitz Bio + Health, First Round Capital, General Atlantic, General Catalyst, Sequoia, Lux Capital, Dragoneer, and Oak HC/FT.
In 2025, top-investor participation was still present but less visibly repeated. The dataset includes names such as HAX / SOSV, USVP, Initialized, BDC Capital, Peak XV, Kindred Ventures, Advance Venture Partners, Bertelsmann India Investments, Fireside Ventures, and Northern Gritstone, but no investor was clearly disclosed in more than one qualifying round.
In 2026 so far, the top-tier and strategic list is still credible. Sofinnova appeared in BrightHeart, Precursor in Xella, Vertex Ventures Israel in Feminai, SJF Ventures and Blue Venture Fund in Origin, Goodwater, Foresite, Serena Ventures, GV, and Felicis in Midi Health, Aegis in Wavelet Medical, Insight Partners and Siemens Healthineers in ScreenPoint Medical, ARTIS in ONTO Health, and M Ventures and Whitecap in Future Fertility.
The conclusion is not that top investors are abandoning femtech. The conclusion is that they are getting more selective. Top investors are showing up where the company has a clear proof environment, such as payer-backed menopause care, AI diagnostics, fertility infrastructure, clinical workflow tools, or scaled care delivery.
Which femtech subcategories are gaining momentum?
The femtech subcategories gaining the most momentum are Hormonal Health Platforms, Women’s Primary Care, and Fertility Care Platforms, with Pregnancy Care Solutions maintaining steadier momentum. The answer depends on whether momentum is measured by current-year dollars, deal count, or full-year structural change.
The freshest 2026 signal points most strongly to Hormonal Health Platforms. From January through May 2026, the category captured about $115M, or 50.9% of all capital, across 4 deals. Over the comparable 2025 period, it captured about $64M, or 28% of capital, across 3 deals. That is a meaningful increase, but the signal is heavily shaped by Midi Health’s $100M round.
Women’s Primary Care is gaining momentum by deal formation rather than capital dominance. In 2026 so far, it produced 6 deals, the highest count of any category, but only about $25M, or 10.9% of capital. That means investors are testing more women’s primary-care models, but most rounds remain small.
Fertility Care Platforms had the strongest full-year momentum from 2024 to 2025. Fertility capital more than doubled from about $147M to about $312M, while deal count rose from 10 to 15. The 2026 year-to-date signal is slower, but the structural momentum remains meaningful because fertility connects to expensive procedures, clinic operations, insurance gaps, and measurable outcomes.
Pregnancy Care Solutions are not the hottest category by capital growth, but they remain durable. In 2026 so far, pregnancy care produced 5 deals and about $35M, compared with 3 deals and about $33M over the comparable 2025 period. The category is strongest when tied to maternal outcomes, prenatal diagnostics, fetal monitoring, or provider workflow.
We cover this subcategory shift in more detail in the deeper analysis of the femtech market.
Which femtech subcategories are losing momentum?
The femtech subcategories losing the most momentum are Menstrual Health Tools and Pelvic Care Devices, while Pregnancy Care Solutions has lost capital momentum relative to its unusually strong 2024 peak without losing strategic relevance.
Menstrual Health Tools show the clearest loss of capital momentum. In 2024, the category captured about $209M, or 25.8% of total capital, across 5 deals. But that was overwhelmingly shaped by Flo Health’s $200M round. In 2025, the category fell to about $17M across 3 deals.
The 2026 year-to-date picture confirms how thin menstrual health funding remains outside exceptional outliers. The category has only one qualifying deal so far, 28x’s $1.5M launch funding. That is a company-formation signal, not a broad scale-financing signal.
Pelvic Care Devices also lost momentum on the full-year comparison, falling from about $46M in 2024 to about $12M in 2025. In 2026 so far, Origin’s $21M Series B makes the category look stronger, but that improvement depends almost entirely on one round.
Pregnancy Care Solutions are more nuanced. Full-year capital fell from about $297M in 2024 to about $34M in 2025, but 2024 was unusually strong because it included large rounds for Maven, Comanche Biopharma, Pomelo Care, and Oula. In 2026, the category has recovered in activity, so the loss is mainly in mega-round intensity, not investor relevance.
This chart, included in our femtech market deck, shows how Flo Health is capturing share in femtech
Which regions are gaining momentum in femtech funding?
North America is gaining the most capital momentum in femtech funding, while Europe is gaining deal-count momentum but losing capital intensity. Smaller regions are becoming more visible, but they remain early and undercapitalized.
From January through May 2026, North America captured about $184M, or 81.7% of total capital, across 11 deals. Over the comparable 2025 period, North America captured about $171M, or 75% of capital, across 12 deals. So North America had slightly fewer deals but more dollars and a higher capital share.
The full-year comparison supports the same story. North America rose from about $464M in 2024 to about $585M in 2025, and its capital share increased from 57.3% to 71.3%. The region is becoming more capital-dense, not just more active.
Europe’s momentum is different. Europe produced 6 deals in 2026 so far, up from 4 over the comparable 2025 period, but capital fell from about $57M to about $33M. That means European femtech company formation is improving, but European companies are not consistently converting into larger rounds.
Asia-Pacific and the Middle East are gaining visibility from a low base. Asia-Pacific moved from 4 deals in 2024 to 6 in 2025, while the Middle East appeared in each period with small but meaningful activity. These regions are no longer absent, but they are not yet scaled funding hubs.
For ongoing regional tracking across North America, Europe, Asia-Pacific, the Middle East, Latin America, and Africa, see the market report covering femtech geography.
Which regions are losing momentum in femtech funding?
Europe is losing capital momentum in the femtech market, even though it is not losing company-formation momentum. The more precise answer is that Europe is becoming more small-check and formation-heavy.
Full-year Europe funding fell from about $324M in 2024 to about $183M in 2025, even as deal count rose from 12 to 16. That means Europe produced more transactions but fewer dollars. The average European deal size fell from about $27M in 2024 to about $11M in 2025.
The freshest comparison confirms the same issue. From January through May 2026, Europe had 6 deals and about $33M. Over the comparable 2025 period, Europe had 4 deals and about $57M. Deal count increased, but capital declined by more than 40%.
North America is not losing momentum. Its full-year capital rose from 2024 to 2025, and its year-to-date capital rose from the comparable early-2025 period to 2026. The region’s deal count is not expanding dramatically, but its capital dominance is strengthening.
Asia-Pacific, Latin America, the Middle East, and Africa are too small to describe with normal momentum language. Their bigger issue is not a directional decline; it is lack of scale in disclosed equity funding.
Is femtech becoming more global or regionally concentrated?
The femtech market is becoming more global by deal presence, but more regionally concentrated by capital. That distinction is essential because more regions are appearing in the funding record, while North America is capturing a larger share of the dollars.
The full-year comparison shows broader geographic participation. In 2024, qualifying deals appeared in North America, Europe, Asia-Pacific, and the Middle East. In 2025, Latin America entered the dataset, Asia-Pacific increased from 4 to 6 deals, the Middle East increased from 1 to 2 deals, and Europe rose from 12 to 16 deals.
But capital became more concentrated in North America. North America captured 57.3% of capital in 2024, 71.3% in 2025, and 81.7% in 2026 so far. That is a decisive movement toward regional concentration by dollars.
The year-to-date 2026 deal-count picture looks more global: North America has 55% of deals, Europe 30%, Asia-Pacific 10%, and the Middle East 5%. But the capital picture is much more concentrated, with North America at 81.7%, Europe at 14.7%, the Middle East at 2.7%, and Asia-Pacific below 1%.
The best interpretation is that femtech is globalizing at the formation layer and concentrating at the scale-financing layer. Entrepreneurs are building across more regions, but large institutional checks remain heavily North American.
This chart, included in our femtech market deck, shows how fertility app adoption has driven growth in the femtech market over time
Is femtech capital moving toward proven winners or new opportunities?
Femtech capital is moving toward proven winners, even though new opportunities continue to appear. The strongest evidence is the persistent gap between first-financing deal share and first-financing capital share.
In 2026 so far, first financings are 35% of deals but only 15% of capital. In full-year 2025, first financings were about 29% of deals but only about 6% of capital. In 2024, first financings were about 39% of deals and still only about 6% of capital.
This means the femtech market consistently funds new companies, but it does not allocate most capital to them. The dollar pool is reserved for companies that have already passed some proof threshold, whether that is clinical validation, payer acceptance, provider adoption, regulatory credibility, commercial traction, or consumer scale.
The largest recent rounds mostly fit the proven-winner pattern. Midi Health’s 2026 Series D+ was growth capital for a scaled women’s health platform, not a speculative first check. Origin’s Series B was follow-on capital for pelvic-floor and women’s musculoskeletal care. Many of the biggest 2025 rounds also went to companies with clearer proof environments, including ReproNovo, Mercy BioAnalytics, Diana Health, Visby Medical, Midi Health, Conceivable Life Sciences, and Gameto.
The better interpretation is that the femtech market is open to new opportunities but capital-disciplined. New startups can get funded, especially if they are clinically specific or infrastructure-like, but the large checks are moving toward proven winners.
Our full market view on proven femtech winners tracks how follow-on capital is concentrating across categories and stages.
Is the femtech market becoming winner-takes-most?
Yes, the femtech market shows winner-takes-most behavior, especially in 2026 so far. The market is active across many companies, but a small number of rounds absorb most of the capital.
In 2026 year-to-date, the largest deal captured 44.4% of all capital, and the top three deals captured 62.6%. The top five deals captured 74.1%, while the bottom half of deals captured only 9.6% of total capital.
The pattern is not new. In 2024, the top three deals captured 49.4% of capital, and the top five captured 64.2%. In 2025, the market was more distributed, with the top three at 21.82% and the top five at 34.61%, but the top ten still captured 61.24% of all dollars.
The real signal is that 2025 was healthier and less concentrated than 2024, while 2026 has become more concentrated again. Midi Health’s $100M round makes the current year look much stronger than the underlying market would look without it.
When reading the femtech market, the rule is simple. Always check top-one, top-three, and bottom-half capital share before drawing a conclusion from total funding.
Is the next wave of femtech winners becoming visible?
The next wave of femtech winners is becoming visible, but it is still early and smaller than the market’s most established leaders. The most promising areas are hybrid healthcare models, diagnostics, fertility infrastructure, women-specific AI tools, and care pathways with measurable clinical or economic value.
In 2026 so far, new and early companies are appearing across multiple categories. Xella is building multi-omic diagnostics using menstrual fluid and blood, Wavelet Medical is working on non-invasive fetal EEG monitoring, Proseek Bio is commercializing ovarian cancer triage, BASE4 Biosciences is building sex-specific biological models, and ONTO Health is developing AI-enabled fertility and longevity care.
These companies are not simply selling broad wellness. They attach femtech to specific proof environments: diagnostics, regulated devices, clinical workflows, fertility care, screening, or provider coordination. That is exactly where the strongest future winners are likely to emerge.
The caveat is that next-wave visibility is not the same as confirmed scale. Many early femtech companies still need to prove reimbursement, clinical adoption, regulatory clearance, repeat usage, or conversion into larger follow-on rounds.
A reliable filter is to ask whether the company owns a narrow, high-cost care pathway. The femtech companies most likely to become durable winners are not necessarily the broadest brands; they are the ones with the clearest workflow depth.
For more context on the new cohort of femtech startups and the signals that separate durable companies from one-off experiments, see the femtech market report.
As this chart shows, and as featured in our femtech market deck, search interest in femtech has increased significantly
Is the femtech funding landscape fragmenting or consolidating?
The femtech funding landscape is fragmenting in participation but consolidating in dollars. More categories, regions, and investors are appearing, while the largest checks still concentrate around a short list of companies.
Investor participation is fragmented. In 2026 so far, about 57 unique disclosed investors appear across 20 deals, but no investor is visibly repeated across the disclosed syndicates. That means the market has breadth but not much repeat-investor density.
Category participation is also broad. In 2026 so far, all six femtech categories have at least one qualifying deal, and Women’s Primary Care, Pregnancy Care Solutions, Hormonal Health Platforms, and Fertility Care Platforms all have multiple deals. That is not a one-category market.
But consolidation is obvious in the capital stack. The top three 2026 deals account for 62.6% of all capital, and the top ten account for 90.4%. That means a broad ecosystem can still produce a highly concentrated funding outcome.
The right way to describe the femtech market is asymmetric. It is fragmenting across investor participation, use cases, and geographies, while consolidating around companies that can show stronger proof and absorb larger follow-on rounds.
Where is investor attention shifting in femtech?
Investor attention in the femtech market is shifting away from broad consumer identity and toward healthcare infrastructure. The strongest rounds increasingly involve diagnostics, clinical AI, care delivery, reimbursement, provider workflows, regulated products, or high-cost fertility and maternity pathways.
Hormonal health is a clear example. Investor attention is strongest when hormonal health moves from education or symptom tracking into care delivery, diagnostics, measurable biomarkers, or clinical management. Midi Health, Allara, Gesynta, Level Zero Health, Xella, Coral, and Osteoboost point to that direction.
Women’s Primary Care is another major shift. The category now includes breast imaging AI, ovarian cancer blood tests, digital gynecology, reproductive navigation, sex-specific biology, and clinical decision support. It is broad, messy, and increasingly investable because many of its use cases attach to high-stakes diagnostic or care-delivery problems.
Fertility remains structurally resilient because it connects to expensive procedures, willingness to pay, clinic operations, insurance gaps, and measurable outcomes. That makes fertility easier to underwrite than broad wellness or education products.
AI is also attracting attention, but only when it is attached to a specific clinical workflow. Prenatal ultrasound, fetal monitoring, breast imaging, fertility assessment, ovarian cancer triage, and reproductive care coordination are more credible than generic AI women’s wellness claims.
For real-time tracking of where investor attention is moving across femtech categories, see the femtech market deck.
All the funding deals in the femtech market from 2024 to April 2026
The table below lists every disclosed funding deal in the supplied femtech dataset from January 2024 through April 2026, covering companies across fertility care, pregnancy care, hormonal health, menstrual health, pelvic care, and women’s primary care.
Each row shows the company, the fundraising date, what the company does, its category, the funding stage, the round size, the region, whether it was a first financing or a follow-on, the tier-1 investor if any, and the announcement source. For the broader market view, see our market deck.
| Company | Date | What they do | Category | Stage | Deal size | Region | First/Follow-on | Tier 1 investor(s) | Source |
|---|---|---|---|---|---|---|---|---|---|
| Future Fertility | Apr 2026 | AI-powered egg quality assessment platform for fertility clinics and IVF decision support. | Fertility Care Platforms | Series A | $4.1M | North America | Follow-on | M Ventures; Whitecap Venture Partners | FemTech Insider |
| BASE4 Biosciences | Apr 2026 | Sex-specific biological atlas and multi-omic platform using a single blood test. | Women’s Primary Care | Seed | $1M | Europe | First financing | Kfund | FemTech Insider |
| ScreenPoint Medical | Apr 2026 | AI-powered breast cancer detection and breast imaging risk assessment platform. | Women’s Primary Care | Unknown | $14M | Europe | Follow-on | Insight Partners; Siemens Healthineers | FemTech Insider |
| ONTO Health | Apr 2026 | AI-enabled, physician-led fertility and longevity care provider. | Fertility Care Platforms | Series A | $20M | North America | First financing | ARTIS | FemTech Insider |
| Osteoboost Health | Apr 2026 | FDA-cleared prescription wearable for low bone density in postmenopausal women. | Hormonal Health Platforms | Unknown | $8M | North America | Follow-on | Portfolia; Emmeline Ventures | FemTech Insider |
| Wavelet Medical | Apr 2026 | Non-invasive, AI-powered fetal EEG monitoring platform for labor and delivery. | Pregnancy Care Solutions | Seed | $7M | North America | First financing | Aegis Ventures | FemTech Insider |
| Proseek Bio | Apr 2026 | Ovarian cancer diagnostic blood test, OC-Triage, for triaging women with suspected ovarian cancer. | Women’s Primary Care | Seed | $1M | Asia-Pacific | First financing | None identified | FemTech Insider |
| SimpliFed | Apr 2026 | Virtual maternal, infant feeding, lactation, and obstetric care platform. | Pregnancy Care Solutions | Series A | $10.8M | North America | Follow-on | None identified from public disclosure | New Market Pitch |
| Flora Fertility | Apr 2026 | Individually owned, portable fertility insurance not tied to employer benefits. | Fertility Care Platforms | Seed | $5M | North America | Follow-on | BDC | FemTech Insider |
| Coral | Apr 2026 | Virtual menopause and midlife women’s health clinic. | Hormonal Health Platforms | Unknown | $2.9M | North America | Follow-on | The51; Diagram | FemTech Insider |
| myStoria | Mar 2026 | AI-plus-human care coordination platform for reproductive-health patients. | Women’s Primary Care | Seed | $1.625M | North America | Follow-on | None identified | FemTech Insider |
| 28x | Mar 2026 | Free, privacy-first period tracking and women’s health app that runs on-device. | Menstrual Health Tools | Seed | $1.5M | Europe | First financing | Philips Foundation | FemTech Insider |
| Pregnolia | Mar 2026 | Pregnancy diagnostic device measuring cervical stiffness to improve preterm birth prediction. | Pregnancy Care Solutions | Unknown | $4.4M | Europe | Follow-on | European Innovation Council, treated as public/deep-tech capital rather than VC tier-1 | FemTech Insider |
| Matresa | Feb 2026 | AI-powered maternal health platform for preventative pregnancy and postpartum support. | Pregnancy Care Solutions | Seed | $0.4M | Europe | First financing | None identified | FemTech Insider |
| Midi Health | Feb 2026 | AI-enabled women’s healthcare platform, originally centered on perimenopause and menopause care, now scaling broader women’s care. | Hormonal Health Platforms | Series D+ | $100M | North America | Follow-on | Goodwater Capital; Foresite Capital; Serena Ventures; GV; Felicis Ventures | Business Wire |
| Origin | Jan 2026 | Pelvic-floor physical therapy and women’s musculoskeletal care delivered through hybrid virtual and in-person care. | Pelvic Care Devices | Series B | $21M | North America | Follow-on | SJF Ventures; Blue Venture Fund | Origin |
| Pinky Promise | Jan 2026 | AI-enabled digital clinic for women in India, covering gynecological, menstrual, fertility, pregnancy, UTI, and PCOS care. | Women’s Primary Care | Seed | $1M | Asia-Pacific | Follow-on | None identified | FemTech Insider |
| Xella Health | Jan 2026 | Women’s precision-health and multi-omic diagnostics platform using menstrual fluid and blood. | Hormonal Health Platforms | Seed | $3.7M | North America | First financing | Precursor Ventures | Xella Health |
| Feminai | Jan 2026 | AI-powered at-home breast cancer screening wearable. | Women’s Primary Care | Seed | $6M | Middle East | Follow-on | Vertex Ventures Israel | FemTech Insider |
| BrightHeart | Jan 2026 | AI platform for prenatal ultrasound, with expert-level fetal screening support. | Pregnancy Care Solutions | Series A | $11.9M | Europe | Follow-on | Sofinnova Partners | BrightHeart |
| IVFmicro | Dec 2025 | IVF culture technology to improve embryo quality and yield per cycle. | Fertility Care Platforms | Seed | $4.4M | Europe | First financing | Northern Gritstone | Tech.eu |
| Inito | Dec 2025 | At-home fertility hormone diagnostics and AI interpretation. | Fertility Care Platforms | Series B | $29M | Asia-Pacific | Follow-on | Bertelsmann India Investments; Fireside Ventures | TechCrunch |
| Emm | Nov 2025 | Connected smart menstrual cup and app. | Menstrual Health Tools | Seed | $9M | Europe | First financing | None clearly identifiable | EU-Startups |
| Clairity | Nov 2025 | FDA-authorized AI breast-cancer risk prediction from mammograms. | Women’s Primary Care | Series B | $43M | North America | Follow-on | Unknown | Business Wire |
| Micro Inno | Nov 2025 | AI-supported gynecological imaging devices. | Women’s Primary Care | Series A | $5M | Asia-Pacific | Follow-on | Unknown | FemTech Insider |
| Midi Health | Oct 2025 | Virtual menopause and perimenopause clinic. | Hormonal Health Platforms | Series C | $50M | North America | Follow-on | Advance Venture Partners | Business Insider |
| Visana Health | Sep 2025 | Virtual women’s-health clinic for endometriosis, PCOS, contraception, menopause, and related care. | Women’s Primary Care | Series A | $24M | North America | Follow-on | Unknown | Business Wire |
| BeSound | Sep 2025 | Breast screening and imaging for dense breast tissue and younger women. | Women’s Primary Care | Seed | $6.8M | North America | First financing | Kindred Ventures | Kindred Ventures |
| Conceivable Life Sciences | Sep 2025 | Robotic IVF lab automation and embryo handling. | Fertility Care Platforms | Series A | $50M | North America | Follow-on | Unknown | Bloomberg |
| Diana Health | Sep 2025 | Maternity and women’s-health care delivery platform. | Women’s Primary Care | Series C | $55M | North America | Follow-on | Unknown | Yahoo Finance |
| Mercy BioAnalytics | Sep 2025 | Blood-based gynecologic and ovarian-cancer detection. | Women’s Primary Care | Series B | $59M | North America | Follow-on | Unknown | GenomeWeb |
| Gameto | Aug 2025 | Fertility biotech developing ovarian-support and reproductive technologies. | Fertility Care Platforms | Series C | $44M | North America | Follow-on | Unknown | FemTech Insider |
| Solence | Jul 2025 | PCOS digital therapeutics and personalized care programs. | Hormonal Health Platforms | Seed | $1.7M | Europe | First financing | Unknown | EU-Startups |
| Ovasave | Jul 2025 | Fertility preservation, hormone testing, and virtual fertility support. | Fertility Care Platforms | Seed | $1.2M | Middle East | First financing | Unknown | Wamda |
| Plenna | Jul 2025 | Hybrid women’s primary-care and gynecology clinics. | Women’s Primary Care | Series A | $6M | Latin America | Follow-on | Unknown | FemTech Insider |
| Plexāā | Jul 2025 | Breast-surgery support and recovery platform. | Women’s Primary Care | Unknown | $4.5M | Europe | Follow-on | Unknown | Bloom43 |
| The Blue Box | Jul 2025 | AI-powered urine-based breast-cancer testing. | Women’s Primary Care | Seed | $3.2M | Europe | First financing | Unknown | Tech.eu |
| Luma Fertility | Jul 2025 | IVF and fertility-care platform in India. | Fertility Care Platforms | Seed | $4M | Asia-Pacific | First financing | Peak XV | FemTech Insider |
| Eli Health | Jun 2025 | Instant saliva-based hormone monitoring system. | Hormonal Health Platforms | Series A | $12M | North America | Follow-on | BDC Capital | Eli Health |
| Janitri | Jun 2025 | Maternal-healthcare monitoring technology. | Pregnancy Care Solutions | Seed | $1.4M | Asia-Pacific | Follow-on | None clearly identifiable | Economic Times |
| Joii | Jun 2025 | AI-powered menstrual blood-volume and clot-size monitoring using specialized pads and app analysis. | Menstrual Health Tools | Seed | $2.6M | Europe | First financing | Unknown | FemTech Insider |
| Samphire Neuroscience | Jun 2025 | Neuromodulation wearable for PMS and menstrual pain symptoms. | Menstrual Health Tools | Seed | $5M | Europe | Follow-on | Unknown | Everything Startups |
| Magcath | Jun 2025 | Women’s incontinence device. | Pelvic Care Devices | Seed | $0.58M | Asia-Pacific | First financing | Unknown | Everything Startups |
| Overture Life | Jun 2025 | Robotic IVF lab automation systems. | Fertility Care Platforms | Series D+ | $20.6M | Europe | Follow-on | Unknown | Everything Startups |
| Escala Medical | Jun 2025 | Pelvic-organ prolapse treatment device. | Pelvic Care Devices | Series A | $4.5M | Middle East | Follow-on | Unknown | FemTech Insider |
| Visby Medical | Jun 2025 | At-home and rapid molecular STI diagnostics with women’s sexual-health relevance. | Women’s Primary Care | Unknown | $55M | North America | Follow-on | Unknown | PR Newswire |
| Ovo Labs | May 2025 | Therapeutics to improve egg quality and IVF outcomes. | Fertility Care Platforms | Seed | $5M | North America | First financing | Unknown | FemTech Insider |
| Hormona | May 2025 | At-home hormone tests and AI hormone insights. | Hormonal Health Platforms | Seed | $8.8M | Europe | Follow-on | Unknown | Sifted |
| ReproNovo | May 2025 | Reproductive-medicine therapeutics for infertility and women’s health. | Fertility Care Platforms | Series A | $65M | Europe | Follow-on | Unknown | EU-Startups |
| UVISA | May 2025 | Light-based treatment device for vaginal infections. | Women’s Primary Care | Seed | $0.65M | Europe | First financing | Unknown | Betahaus |
| Valerie | May 2025 | Perimenopause wellness and symptom-support platform. | Hormonal Health Platforms | Seed | $0.645M | Europe | First financing | Unknown | Everything Startups |
| Teal Health | May 2025 | At-home cervical-cancer screening and self-collection workflow. | Women’s Primary Care | Unknown | $10M | North America | Follow-on | Unknown | TechCrunch |
| Cofertility | Apr 2025 | Egg-freezing and egg-donation platform. | Fertility Care Platforms | Series A | $7.25M | North America | Follow-on | Initialized | FinSMEs |
| Uresta | Mar 2025 | Reusable device for stress urinary incontinence. | Pelvic Care Devices | Unknown | $3M | North America | Follow-on | Unknown | Business Wire |
| Fizimed | Mar 2025 | Connected pelvic-floor and women’s-health devices. | Pelvic Care Devices | Unknown | $4.4M | Europe | Follow-on | Unknown | Bpifrance |
| Millie | Feb 2025 | Tech-enabled maternity-care model. | Pregnancy Care Solutions | Series A | $12M | North America | Follow-on | Unknown | Business Wire |
| Delfina | Feb 2025 | AI-powered maternal-health platform for pregnancy risk prediction and care interventions. | Pregnancy Care Solutions | Series A | $17M | North America | Follow-on | USVP | Delfina |
| Level Zero Health | Feb 2025 | Wearable continuous hormone-monitoring biosensor platform. | Hormonal Health Platforms | Seed | $6.9M | Europe | First financing | HAX / SOSV | TechCrunch |
| Ataraxis AI | Jan 2025 | AI breast-cancer precision medicine and clinical decision support. | Women’s Primary Care | Series A | $20.4M | North America | Follow-on | Unknown | Business Wire |
| Arva Health | Jan 2025 | Modern fertility clinics, testing, consultations, IVF, and coaching. | Fertility Care Platforms | Seed | $1M | Asia-Pacific | First financing | Unknown | FemTech Insider |
| SimpliFed | Jan 2025 | Pregnancy and postpartum feeding-support platform. | Pregnancy Care Solutions | Unknown | $4M | North America | Follow-on | Unknown | Everything Startups |
| PinkDx | Jan 2025 | Diagnostics for gynecologic cancers. | Women’s Primary Care | Series A | $5M | North America | Follow-on | Unknown | PR Newswire |
| Gaia | Jan 2025 | Fertility insurance and IVF affordability platform. | Fertility Care Platforms | Series A | $14M | Europe | Follow-on | Unknown | Everything Startups |
| Kegg / Lady Technologies | Jan 2025 | Cervical-fluid fertility tracker for fertile-window prediction. | Fertility Care Platforms | Unknown | $6.5M | North America | Follow-on | Unknown | Everything Startups |
| Twentyeight Health | Jan 2025 | Reproductive-health telehealth for birth control, STI testing, and related women’s care. | Women’s Primary Care | Series A | $10M | North America | Follow-on | None clearly identifiable | FemTech Insider |
| Sunfish | Jan 2025 | Fertility financing to make IVF more accessible and predictable. | Fertility Care Platforms | Series A | $10M | North America | Follow-on | Unknown | Axios |
| Conceivable Life Sciences | Jan 2025 | Robotic and AI IVF lab automation. | Fertility Care Platforms | Series A | $50M | North America | Follow-on | Unknown | Axios |
| Allara Health | Jan 2025 | Virtual care for PCOS, endometriosis, and chronic hormonal conditions. | Hormonal Health Platforms | Series B | $26M | North America | Follow-on | Unknown | PR Newswire |
| Gesynta Pharma | Jan 2025 | Non-hormonal drug development for endometriosis-related chronic pelvic pain. | Hormonal Health Platforms | Series B | $31.5M | Europe | Follow-on | Unknown | FemTech Insider |
| Lushi | Dec 2024 | Fertility concierge and injection support for IVF and egg freezing. | Fertility Care Platforms | Seed | $5M | North America | First financing | None clearly disclosed | Business Wire |
| Pelvital | Dec 2024 | Intravaginal device for stress urinary incontinence. | Pelvic Care Devices | Series B | $2.32M | North America | Follow-on | None disclosed | Twin Cities Business |
| Nua Surgical | Nov 2024 | Surgical retractor designed to improve safety during Caesarean sections. | Pregnancy Care Solutions | Seed | $7.02M | Europe | Follow-on | None clearly disclosed | FemTech Insider |
| Nua | Nov 2024 | Period, sanitary, and postpartum products. | Menstrual Health Tools | Series C | $4.01M | Asia-Pacific | Follow-on | None clearly disclosed | FemTech Insider |
| Parallel Fluidics | Nov 2024 | Microfluidic technology to improve IVF fertilization processes. | Fertility Care Platforms | Seed | $7M | North America | Follow-on | None clearly disclosed | Everything Startups |
| FertilAI | Nov 2024 | AI platform helping fertility clinics optimize IVF outcomes. | Fertility Care Platforms | Seed | $4.5M | Asia-Pacific | First financing | None disclosed | FemTech Insider |
| Alloy | Nov 2024 | Telehealth menopause care and hormone therapy platform. | Hormonal Health Platforms | Series A | $16M | North America | Follow-on | None clearly disclosed | Fortune |
| India IVF | Oct 2024 | Fertility platform expanding IVF services across India. | Fertility Care Platforms | Unknown | $1.25M | Asia-Pacific | Follow-on | None disclosed | PR Newswire |
| Persperity Health | Oct 2024 | Sweat-sensing wearable for real-time hormone monitoring in women. | Hormonal Health Platforms | Seed | $1M | North America | First financing | None disclosed | PR Newswire |
| Vara | Oct 2024 | AI mammography screening for earlier breast cancer detection. | Women’s Primary Care | Series B | $8.9M | Europe | Follow-on | None clearly disclosed | GlobeNewswire |
| Maven Clinic | Oct 2024 | Virtual clinic and benefits platform for fertility, maternity, parenting, and menopause. | Pregnancy Care Solutions | Series D+ | $125M | North America | Follow-on | General Catalyst; Sequoia; Lux Capital; Dragoneer; Oak HC/FT | PR Newswire |
| Hyivy Health | Sep 2024 | Remote therapy and monitoring for pelvic floor dysfunction and chronic pelvic pain. | Pelvic Care Devices | Seed | $2M | North America | Follow-on | None disclosed | Access Newswire |
| Cercle | Sep 2024 | AI platform turning women’s healthcare data into clinical and business insights. | Women’s Primary Care | Seed | $6M | North America | First financing | None clearly disclosed | Cercle |
| OCON Therapeutics | Aug 2024 | Intrauterine drug delivery systems for contraception and gynecological conditions. | Fertility Care Platforms | Growth Equity | $10M | Middle East | Follow-on | None clearly disclosed | FemTech Insider |
| Laiqa Wellness | Aug 2024 | Hormonal health tracking with cycle-synced care plans. | Hormonal Health Platforms | Seed | $1.78M | Asia-Pacific | First financing | None disclosed | FemTech Insider |
| Flo Health | Jul 2024 | Period, fertility, pregnancy, and menopause tracking app. | Menstrual Health Tools | Series C | $200M | Europe | Follow-on | General Atlantic | General Atlantic |
| Materna Medical | Jun 2024 | Pelvic organ prolapse and pelvic floor medical devices. | Pelvic Care Devices | Series B | $20M | North America | Follow-on | None clearly disclosed | Business Wire |
| Pomelo Care | Jun 2024 | Virtual maternal and newborn care from preconception through infancy. | Pregnancy Care Solutions | Series B | $46M | North America | Follow-on | a16z; First Round Capital | Pomelo Care |
| Axena Health | Jun 2024 | At-home device for stress urinary and fecal incontinence in women. | Pelvic Care Devices | Series A | $9.4M | North America | Follow-on | AXA IM Alts | Axena Health |
| Gameto | May 2024 | Reproductive biotech developing novel fertility treatments. | Fertility Care Platforms | Series B | $33M | North America | Follow-on | RA Capital; Insight Partners; Two Sigma Ventures | PR Newswire |
| Natural Cycles | May 2024 | FDA-cleared digital contraceptive and fertility tracking app. | Fertility Care Platforms | Series C | $54.86M | Europe | Follow-on | Point72; EQT Ventures; J.P. Morgan | Lauxera |
| May Health | May 2024 | PCOS-related fertility therapy using ovarian rebalancing. | Fertility Care Platforms | Series B | $25M | Europe | Follow-on | Sofinnova Partners | Business Wire |
| Midi Health | Apr 2024 | Insurance-covered virtual menopause and perimenopause clinic. | Hormonal Health Platforms | Series B | $65M | North America | Follow-on | Emerson Collective; GV; Felicis | Midi Health |
| Ovom Care | Apr 2024 | AI-enabled hybrid fertility care and IVF clinic model. | Fertility Care Platforms | Seed | $5.18M | Europe | First financing | None clearly disclosed | FemTech Insider |
| Elvie | Apr 2024 | Women’s health devices including wearable breast pumps and pelvic floor trainers. | Pelvic Care Devices | Series C | $12.19M | Europe | Follow-on | None clearly disclosed | FemTech Insider |
| Chiyo | Mar 2024 | Personalized nutrition and meal delivery for pregnancy and postpartum. | Pregnancy Care Solutions | Seed | $3M | North America | First financing | None clearly disclosed | TechCrunch |
| Hertility Health | Mar 2024 | At-home fertility testing and care pathways. | Fertility Care Platforms | Unknown | $0.99M | Europe | Follow-on | None disclosed | Beauhurst |
| Omena | Mar 2024 | Menopause support platform with symptom tracking and teleconsultations. | Hormonal Health Platforms | Seed | $0.65M | Europe | First financing | None disclosed | FemTech Insider |
| FamilyWell Health | Feb 2024 | Tech-enabled maternal mental health care integrated into OB/GYN settings. | Pregnancy Care Solutions | Seed | $4.3M | North America | First institutional financing | None clearly disclosed | FemTech Insider |
| Sorella | Feb 2024 | Hybrid women’s health clinic network in France. | Women’s Primary Care | Seed | $5.4M | Europe | First financing | None clearly disclosed | EU-Startups |
| Ema App | Feb 2024 | Conversational AI platform for women’s health and wellness. | Women’s Primary Care | Unknown | $2M | North America | Follow-on bridge | Techstars; Hearst Labs | EIN Presswire |
| Oula | Feb 2024 | Hybrid maternity clinics combining midwifery and obstetrics. | Pregnancy Care Solutions | Series B | $28M | North America | Follow-on | GV; 8VC | PR Newswire |
| Samphire Neuroscience | Feb 2024 | Wearable neuromodulation device for PMS/PMDD and menstrual pain. | Menstrual Health Tools | Seed | $2.29M | Europe | First financing | SOSV | FemTech Insider |
| Elektra Health | Feb 2024 | Virtual menopause care with education, coaching, and clinician access. | Hormonal Health Platforms | Seed | $3.3M | North America | Follow-on | None clearly disclosed | MedCity News |
| DeepLook Medical | Feb 2024 | AI-enabled visual enhancement for cancer detection in dense breast tissue. | Women’s Primary Care | Seed | $1.7M | North America | First financing assumed | None clearly disclosed | Boston Harbor Angels |
| Essence App | Feb 2024 | Menstrual-cycle-aware workplace performance and wellbeing app. | Menstrual Health Tools | Seed | $0.6M | North America | First financing | None clearly disclosed | FemTech Insider |
| Unfabled | Feb 2024 | Women’s health commerce platform focused on menstrual and reproductive care products. | Menstrual Health Tools | Seed | $1.63M | Europe | First financing | None disclosed | Beauhurst |
| Comanche Biopharma | Jan 2024 | siRNA therapy targeting a root cause of preeclampsia. | Pregnancy Care Solutions | Series B | $75M | North America | Follow-on | NEA; GV; F-Prime Capital; Atlas Venture | Comanche Biopharma |
| Annabella | Jan 2024 | First-of-its-kind breast pump entering the U.S. market. | Pregnancy Care Solutions | Seed | $8.5M | North America | First financing | None clearly disclosed | Business Wire |
INSIGHTS
The insights below come from reviewing publicly disclosed equity rounds in the femtech market across full-year 2024, full-year 2025, and January through May 2026.
- The femtech market’s headline capital totals are less informative than concentration-adjusted funding. A year with more than $800M in capital can still be fragile if the top three deals capture half the market or if one company represents more than 40% of current-year funding.
- Deal count is a better indicator of founder formation than market maturity. The rise from 39 deals in 2024 to 49 deals in 2025 shows more activity, but the fall in average round size shows that more financings did not translate into broader scale-up conviction.
- The femtech market is consistently a barbell market. Seed-stage activity remains abundant, while large rounds go to a small number of clinically or commercially validated winners; the middle remains thinner than a mature venture market would suggest.
- The strongest underwriting rule is that women’s health is not enough. The strongest rounds attach women-specific health needs to payer workflows, provider infrastructure, regulated diagnostics, procedure economics, or large recurring consumer revenue.
- Hormonal health is becoming more investable when it moves from symptom tracking to care delivery, diagnostics, or measurable biomarkers. The category’s best-funded companies are increasingly clinical and economic, not just educational or lifestyle-oriented.
- Menstrual health has a scale problem outside exceptional consumer platforms. Flo Health’s $200M round made menstrual health look capital-rich in 2024, but 2025 and 2026 show that most menstrual tools still raise small early-stage rounds.
- Fertility is one of the most structurally resilient femtech categories. It connects to expensive procedures, willingness to pay, clinic operations, insurance gaps, and measurable outcomes, which makes it easier to diligence than broad wellness products.
- Women’s Primary Care is the broadest emerging opportunity, but also the messiest category. Breast screening AI, ovarian cancer blood tests, digital gynecology, reproductive navigation, and sex-specific biology sit in the same bucket despite having very different risk profiles.
- Pregnancy Care Solutions are moving from broad maternity platforms toward sharper clinical workflows. Prenatal ultrasound AI, fetal EEG, cervical stiffness diagnostics, postpartum care, and lactation support suggest investors prefer tools that can show measurable clinical or operational impact.
- Pelvic care remains undercapitalized relative to medical need. The category has recurring deal activity, but capital levels remain low unless a company can present a clearer care-delivery, adoption, or reimbursement pathway.
- North America’s advantage is not just more startups; it is larger checks. North America’s 2026 year-to-date deal share is 55%, but its capital share is 81.7%, showing that the region is where femtech companies are most likely to receive scale financing.
- Europe is becoming a formation engine but not a scale-financing engine. European deal count rose from 2024 to 2025 and again in early 2026, but European capital share declined, which suggests promising startups are not consistently converting into large rounds.
- Investor fragmentation is one of the femtech market’s most important structural weaknesses. Many investors appear once, but few appear repeatedly, which limits category learning, follow-on confidence, and market-specific underwriting expertise.
- Top-tier investors are participating, but they are not validating the entire femtech category equally. Their participation clusters around companies with clinical severity, infrastructure value, payer relevance, or large platform potential.
- Median round size is often more useful than average round size in this market. The gap between a $4.7M median and an $11.3M average in 2026 shows that most companies are raising far less than the headline average implies.
- The market is shifting from consumer identity to healthcare infrastructure. The biggest and most credible rounds increasingly involve diagnostics, clinical AI, care delivery, reimbursement, provider workflows, or regulated products.
- AI is a funding accelerant only when attached to a specific clinical workflow. Prenatal ultrasound, fetal monitoring, breast imaging, fertility assessment, and ovarian cancer triage are more credible than generic AI women’s wellness claims.
- The femtech market’s strongest companies tend to own a narrow, high-cost care pathway rather than a broad lifestyle proposition. Investors are rewarding depth of workflow more than breadth of brand.
- The biggest bottleneck is conversion from seed activity to institutional scale-up rounds. Seed formation is healthy, but relatively few companies are crossing into large Series B or later financings.
- The most defensible forecast is selective growth, not a broad boom. The femtech market should keep producing funded startups, but large checks will likely remain concentrated in companies that can prove clinical value, economic value, or platform-scale retention.
- Femtech is becoming less of a single category and more of a financing layer across multiple healthcare verticals. Fertility, oncology, menopause, maternity, pelvic health, and diagnostics now behave like different markets with different proof standards.
This chart, included in our femtech market deck, shows how cycle tracking app technology has evolved over time
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this femtech funding tracker by reviewing publicly disclosed equity rounds raised by pure-play femtech companies between January 2024 and May 2026. A company counts as pure-play when more than 80% of its activity is dedicated to technology-enabled products or services addressing women’s reproductive health or other female-specific health needs.
We applied four core filters to build the dataset. First, we only included equity rounds, so grants, debt, structured financings, SPAC transactions, acquisitions, and business combinations are excluded. Second, we only counted disclosed rounds of $300K or more. Third, we only kept pure-play femtech companies across Fertility Care Platforms, Pregnancy Care Solutions, Menstrual Health Tools, Hormonal Health Platforms, Pelvic Care Devices, and Women’s Primary Care. And fourth, every entry had to be confirmed by a direct company announcement, a press release, a tier-1 media report, a specialized industry source, or a relevant regional publication.
We excluded undisclosed-amount rounds because including them would distort dollar-based metrics such as average round size, median round size, category capital share, and concentration ratios. We also excluded non-pure-play general healthcare, wellness, family-health, infant-only, beauty, supplement, and mental-health companies when women’s reproductive or female-specific health was not clearly more than 80% of the business activity. The final dataset is therefore a public-source funding tracker, not a private cap-table audit, and privately raised rounds that were never publicly announced are necessarily missing.
Related blog posts
- The latest developments in the femtech market
- The most recent news in the femtech market
- What is the true size of the femtech market?
- The latest funding news in the femtech market
- How funding activity has evolved in the femtech market
- Which companies have raised the most funding in the femtech market?
- Which companies are the most valued in the femtech market?
